Adherence to biologic DMARD therapies in rheumatoid arthritis

Bibliography

• Smolen JS, Aletaha D, Koeller M, New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74
   PubMed Web of Science ®Google Scholar
• Bingham CO III. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp J Dis 2008;66:210-15
   PubMedGoogle Scholar
• Furst DE, Keystone EC, Kirkham B, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl 3):iii2-25
   PubMedGoogle Scholar
• Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15(Suppl 17):S27-38
   PubMed Web of Science ®Google Scholar
• Zink A, Strangfeld A, Schneider M, Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54(11):3399-407
   PubMed Web of Science ®Google Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423-34
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chung CP, Arbogast PG, Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45(10 Suppl 2):S66-76
   PubMed Web of Science ®Google Scholar
• Hughes D, Cowell W, Koncz T, Cramer J. International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509
   PubMed Web of Science ®Google Scholar
• van den Bemt BJF, van Lankveld GJMW. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 2007;3:681
   PubMedGoogle Scholar
• Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402
   PubMed Web of Science ®Google Scholar
• Burrell A, Wong P, Ollendorf D, Defining compliance/adherence and persistence. ISPOR Special Interest Working Group. Value Health 2005;8:A194-195
   Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453-7
   PubMed Web of Science ®Google Scholar
• Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77
   PubMed Web of Science ®Google Scholar
• Curkendall S, Patel V, Gleeson M, Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26
   PubMed Web of Science ®Google Scholar
• Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritispatients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6 Suppl):S136-143
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
   PubMed Web of Science ®Google Scholar
• Yazici Y, Krasnokutsky S, Barnes JP, Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L. BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8(1):R29
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Dehler S, Ciurea A, Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8
   PubMed Web of Science ®Google Scholar
• Brocq O, Roux CH, Albert C, TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8(6):R174
   PubMedGoogle Scholar
• Hetland ML, Christensen IJ, Tarp U, Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Zaccara E, Gorla R, TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 2009;1173:837-46
   PubMed Web of Science ®Google Scholar
• Geborek P, Crnkic M, Petersson IF, Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8
   PubMed Web of Science ®Google Scholar
• Flendrie M, Creemers MC, Welsing PM, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii30-33
   PubMedGoogle Scholar
• Duclos M, Gossec L, Ruyssen-Witrand A, Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. Rheumatol 2006;33:2433-8
   Web of Science ®Google Scholar
• Zink A, Listing J, Kary S, Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Unkerskov J, Linde L, Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 2007;36:151-4
   PubMed Web of Science ®Google Scholar
• Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009;15:34-44
   PubMed Web of Science ®Google Scholar
• Munro SA, Lewin SA, Smith HJ, Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4(7):e238
   PubMed Web of Science ®Google Scholar
• Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 2009;14:185-90
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66
   PubMed Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar